Ribociclib

About

Therapy type: Targeted therapy

Therapy strategy: CDK4/6 inhibition

Mappings

NCI Thesaurus: Ribociclib (coding:ncit:C95701)

RxNorm: ribociclib (coding:rxcui:1873916, coding:omop:1592911)

SNOMED: Ribociclib (coding:sctid:732257004, coding:omop:37115766)

View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this therapy.

Organizations Biomarkers Cancer types Therapies
EMA (1) FDA (2) HSE (1) ER positive, HER2-negative Invasive Breast Carcinoma Fulvestrant, Ribociclib
EMA (1) FDA (2) HSE (1) HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant, Ribociclib
EMA (1) FDA (2) HSE (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant, Ribociclib
FDA (1) ER positive, HER2-negative Invasive Breast Carcinoma Anastrozole, Ribociclib
FDA (1) HER2-negative, PR positive Invasive Breast Carcinoma Anastrozole, Ribociclib
FDA (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Anastrozole, Ribociclib
EMA (1) FDA (1) HSE (2) ER positive, HER2-negative Invasive Breast Carcinoma Letrozole, Ribociclib
EMA (1) FDA (1) HSE (2) HER2-negative, PR positive Invasive Breast Carcinoma Letrozole, Ribociclib
EMA (1) FDA (1) HSE (2) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Letrozole, Ribociclib
EMA (1) FDA (1) HSE (1) ER positive, HER2-negative Invasive Breast Carcinoma Anastrozole, Goserelin, Ribociclib
EMA (1) FDA (1) HSE (1) HER2-negative, PR positive Invasive Breast Carcinoma Anastrozole, Goserelin, Ribociclib
EMA (1) FDA (1) HSE (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Anastrozole, Goserelin, Ribociclib
EMA (1) FDA (1) HSE (1) ER positive, HER2-negative Invasive Breast Carcinoma Goserelin, Letrozole, Ribociclib
EMA (1) FDA (1) HSE (1) HER2-negative, PR positive Invasive Breast Carcinoma Goserelin, Letrozole, Ribociclib
EMA (1) FDA (1) HSE (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Goserelin, Letrozole, Ribociclib
EMA (1) ER positive, ESR1 activating variants, HER2-negative Invasive Breast Carcinoma Camizestrant, Ribociclib